Clinical experience with monoclonal antibodies to epidermal growth factor receptor

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) activation is key in malignant neoplasm proliferation and survival.
• Target-based therapeutics, particularly those inhibiting EGFR, show significant clinical relevance.

Purpose of the Study:

• To review the role of EGFR in cancer.
• To discuss the development and clinical application of EGFR-targeting monoclonal antibodies (mAbs).

Main Methods:

• Review of recent knowledge on EGFR activation pathways.
• Analysis of clinical development stages for EGFR-targeting mAbs.

Main Results:

• EGFR plays a fundamental role in cancer cell proliferation and survival.
• Monoclonal antibodies blocking ligand binding to EGFR effectively arrest cancer cell proliferation and induce tumor regression.
• Cetuximab, a chimeric mAb, is approved for advanced colorectal cancer.
• Other EGFR-targeting mAbs like panitumumab are in advanced clinical development.

Conclusions:

• Targeting EGFR with monoclonal antibodies is a clinically relevant therapeutic strategy for various cancers.
• EGFR inhibitors offer a promising approach for managing malignant neoplasms.